

**SOLUBLE TRIGGERING RECEPTOR EXPRESSED ON
MYELOID CELL-1 (TREM-1) IN PEDIATRIC PATIENTS
WITH VENTILATOR-ASSOCIATED PNEUMONIA**

Thesis

Submitted for partial fulfillment of

Master Degree in Pediatrics

By

Marwa Mohammed Effat Hassan

M.B., B.CH, (2004)

Under Supervision of

Professor Doctor /Tarek Ahmed Abd-El-Gawad

Professor of pediatrics

Faculty of Medicine, Ain Shams University

Professor Doctor /Hanan Mohammed Ibrahim

Professor of pediatrics

Faculty of medicine, Ain Shams University

Professor Doctor / Manal Mohammed Abd-El-Aziz

Professor of clinical pathology

Faculty of medicine, Ain Shams University

2010

ACKNOWLEDGEMENT

Praise be to ALLAH, the Merciful, the Compassionate for all the countless gifts I have been offered. One of these gifts is accomplishing this research work.

*I wish to express my deepest gratitude and sincere appreciation towards **Prof. Dr. Tarek Abdel-Gawwad**, professor of pediatrics, Faculty of Medicine, Ain Shams University, for his valuable suggestions and close supervision. He generously offered much of his valuable time to direct this thesis.*

*I am so grateful to **Prof. Dr. Hanan M. Ibrahim**, professor of pediatrics, Faculty of medicine, Ain Shams University, who devoted much of her precious time, effort and generous advice for the completion of this work. Many thanks to her experienced guidance and encouragement.*

*I am so grateful to **Prof. Dr. Manal M. Abdel-aziz**, professor of clinical pathology, Faculty of Medicine, Ain Shams University, for her close and meticulous supervision, broad understanding and friendly encouragement.*

Further more; I would like to convey my special thanks to my father, my mother, my husband and my brothers for their constant support. Special thanks to my elder brother Dr. Waleed Effat for his generous aid in accomplishing the statistical results of this thesis.

Contents

Acknowledgement
List of figures
List of tables
List of abbreviations
Introduction	1
Aim of the study	3
Ventilator-Associated Pneumonia	4
Pathogenesis	9
Risk factors	12
Diagnosis	16
Treatment.....	27
Pharmacological measures for preventing VAP	32
Nonpharmacological measures for preventing vap	35
Blind bronchoalveolar lavage.....	49
TREM-1	59
Patients and methods	71
Results	83
Description of the demographic data of patients and controls.....	85
Discussion.....	119
Summary	131
Recommendations	134
References	135
Arabic summary	153

List of figures

Figure 1: Causes of ventilator associated pneumonia.....	6
Figure 2: Risk factors for colonization of the aerodigestive tract and trachea before the development of tracheobronchitis and nosocomial/ventilator-associated pneumonia	10
Figure 3 : Chest radiograph of a patient with late-onset ventilator-associated pneumonia with pleural effusion involving the left lower lobe.....	20
Figure 4: Typical chest radiograph of a patient with ventilator-associated pneumonia.....	20
Figure 5: ProBAL© PSB by Mill-Rose.com	23
Figure 6: Algorithm for treatment of VAP	31
Figure 7: measures to prevent VAP regarding intubation	35
Figure 8: Subglottic secretions drainage.....	37
Figure 9: Closed tracheal suctioning system	44
Figure 10 : Mini BAL	49
Figure 11: CombiCath® by PlastiMed	50
Figure 12: Kimberly-Clark* BAL CATH* catheter.....	51
Figure 13: Schematic representation of TREM-1	62
Figure 14: Expression of TREM-1	63
Figure 15: TREM-1.....	66
Figure 16 : Bar graph showing the sex distribution among studied patients ...	86
Figure 17: graph showing the frequency of different causes of ICU admission among studied patients.....	87
Figure 18: Comparison between VAP and Non VAP patients regarding the mean ICU stay.....	91
Figure 19: Comparison between VAP and Non VAP patients as regards the mean duration of mechanical ventilation.....	92
Figure 20: bar graphs showing the number of patients categorized by the CPIS score.	93
Figure 21: Comparison between VAP patients and Non VAP patients as regards the mean PRISM score.....	94
Figure 22: Comparison between VAP and Non VAP patients regarding the mean TREM-1	97

Figure 23: Comparison between survivors and non survivors as regards mean duration of ICU stay.....	100
Figure 24: Comparison between survivors and non survivors as regards mean duration of mechanical ventilation.....	101
Figure 25: bar graph showing the frequency of mortality among VAP patients regarding CPIS score.	102
Figure 26: Comparison between survivors and non survivors as regards the mean PRISM score	103
Figure 27: Comparison between survivors and non survivors regarding the mean TREM-1	105
Figure 28: Correlation between the temperature and TREM-1 in VAP patients	107
Figure 29: Correlation between the TLC and TREM-1 in VAP patients	108
Figure 30: Correlation between the CPIS and TREM-1 in VAP patients	109
Figure 31: Correlation between the temperature and TREM-1 in survivors .	111
Figure 32: Correlation between the TLC and TREM-1 in survivors.....	112
Figure 33: Correlation between the CPIS and TREM-1 in survivors (VAP)	113
Figure 34: Correlation between CPIS and TREM 1 in non survivors	115
Figure 35: ROC curve of TREM-1 in diagnosis of VAP.....	117
Figure 36: ROC curve of TREM-1 in the prognosis of VAP	118

List of tables

Table 1: Etiology- select risk factors for pathogens.....	8
Table 2: CPIS score.....	18
Table 3: Comparison of Techniques	26
Table 4: CPIS Score calculator	73
Table 5: PRISM score	75
Table 6: Gender distribution of the studied subjects:.....	85
Table 7: Age distribution of the studied subjects:.....	86
Table 8: Frequency table of different diseases in the included study groups.....	87
Table 9: The pathogenic microorganisms isolated in VAP patients	88
Table 10: Antibiotic susceptibility testing of the isolated coagulase -ve Staph	89
Table 11: Comparison between VAP and Non VAP patients regarding the clinical data	90
Table 12: Comparison between patients and controls regarding the CPIS score.....	93
Table 13: Comparison between VAP and non VAP patients regarding the PRISM score.	94
Table 14: Comparison between VAP and Non VAP patients regarding mortality rates	95
Table 15: Comparison between VAP and Non VAP regarding the routine laboratory investigations.....	95
Table 16: Comparison between VAP and Non VAP patients regarding Blood gases	96
Table 17: TREM-1 results regarding VAP patients and non VAP patients	96
Table 18: Comparison between survivor and non survivor patients regarding diagnosis	98
Table 19: Comparison survivor and non survivor patients regarding the clinical data	99
Table 20: Comparison between survivor and non survivor patients regarding the mean CPIS score.....	101
Table 21: comparison between survivors and non survivors regarding mean PRISM score.	102
Table 22: Comparison between survivors and non survivors regarding routine laboratory data.....	103
Table 23: Comparison between survivors and non survivors regarding the Blood gases	104
Table 24: TREM-1 results regarding survivors and non survivors	104
Table 25: Correlation coefficient between TREM-1 and all the studied parameters among VAP patients	106

Table 26: correlation coefficient between TREM-1 and all studied parameters among survivor patients	110
Table 27: Correlation coefficient between TREM-1 and all studied parameters among non survivor patients	114
Table 28: Multivariate analysis: Logistic regression model	116

List of abbreviations

ALI	Acute lung injury
ARDS	Acute respiratory distress syndrome
BAL	Broncho-alveolar lavage
Ca ²⁺	Calcium
Cath	Catheter
CD1a	Cluster of differentiation 1a
cDNA	Complementary DNA
COPD	Chronic obstructive pulmonary disease
CPIS	Clinical pulmonary infection score
CRP	C-reactive protein
CTSS	Closed tracheal suctioning system
DAP12	Adapter protein 12
DCs	Dendritic cells
ERK	Extracellular signal-regulated kinases
ET	Endotracheal tube
ETA	Endotracheal aspirate
FEV	Forced expiratory volume
FiO ₂	Fraction of Inspired Oxygen
FMLP	N-formyl-methionylleucyl-phenylalanine
GER	Gastro-esophageal reflux
GNB	Gram negative bacilli
Hb	Haemoglobin
HCO ₃	Bicarbonate
HH	Heated humidifiers
HIV	Human Immunodeficiency Virus
HME	Heat and moisture exchanger
HMG-1	High mobility group -1
ICU	Intensive care unit
IgG	Immunoglobulin G

IL-1a	Interlukin 1a
IL-1b	Interlukin-1b
IL-8	Interlukin-8
ITIM	Immunoreceptor Tyrosine based Inhibition Motif
LES	Lower esophageal sphincter
LPS	Lipopolysacharide
MAb	Monoclonal antibody
MCP-1	Monocyte chemoattractant-1
MCP-3	Monocyte chemoattractant-3
MRSA	Methicillin resistant staphylococcus aureus
MSSA	Methicillin sensitive staphylococcus aureus
MV	Mechanical ventilation
NIMV	Noninvasive mechanical ventilation
NK	Natural killer
NKp44	Natural killer p44
OTSS	Open tracheal suctioning system
Pao2	Partial Pressure of Oxygen in Arterial Blood
PCo2	Partial carbon dioxide tension
PEEP	Peak end expiratory pressure
PICU	Paediatric intensive care unit
PRISM	Pediatric risk of mortality score
PSB	Protected specimen brush
ROC	Receiver Operator Characteristics curve
SD	Standard deviation
SDD	Selective digestive decontamination
SSD	Subglottic secrtions drainage
TBB	Transbronchial biopsy
TLC	Total leucocytic count
TLRs	Toll-like receptors
TNF-a	Tumor necrotising factor-a
TREM-1	Triggering receptor expressed on myloid cell 1

TREM-2	Triggering receptor expressed on myloid cell -2
TREM-3	Triggering receptor expressed on myloid cell-3
VAP	Ventilator associated pneumonia

Introduction

Ventilator associated pneumonia (VAP) is a common and highly morbid condition in the intensive care unit, affecting up to 27% of mechanically ventilated patients(*Guide lines., 2005*)

Several risk factors have been reported to be associated with VAP, including the duration of mechanical ventilation, and the presence of chronic pulmonary disease, sepsis, and acute respiratory distress syndrome. (*Jejeriana E et al., 2006*)

Mortality rates in patients with VAP range from 20 to 50% and may reach more than 70% when the infection is caused by multi- resistant and invasive pathogens. Therefore, this complication of mechanical ventilation requires a prompt diagnoses and adequate antibiotic treatment. (*Heyland D K et al., 1999*)

Management of ventilator-associated pneumonia needs to balance the avoidance of unnecessary antibiotic overuse with the provision of adequate initial empiric therapy (*Vidaaur et al., 2005*)

The detection of the causative organism is imperative for guiding an appropriate therapy (*Joanas et al., 2001*). Triggering receptor expressed on myeloid cells (TREM-1) is a member of the immunoglobulin super family. (*Papazian L et al., 1995*)

TREM-1 mediates the acute inflammatory response to microbial products. the human tissues infected with bacteria are infiltrated with neutrophils and monocytes that express high levels of TREM-1. TREM-1 is also shed by the membrane of activated phagocytes, and can be found in a soluble form in body fluids. (*Croce MA et al., 2006*)

The inflammatory response during pneumonia is a complex process. The knowledge of this response may be of clinical importance in determining more efficacious therapy. (*Croce MA et al., 2006*).

Aim of the study

The aim of this study is to evaluate the utility of (TREM-1) in the diagnosis of ventilator-associated pneumonia (VAP) in broncho-alveolar lavage (BAL) fluid.

Ventilator-Associated Pneumonia

Definition:

Ventilator-associated pneumonia (VAP) is nosocomial pneumonia that has developed in patients who are receiving mechanical ventilation.

VAP is divided into early onset pneumonia which occurs within 48 to 72 hours after tracheal intubation, it often results from aspiration, which complicates the intubation process. (*Chaster J et al; 2007*)

VAP that occurs after this period is considered late-onset pneumonia, which is usually caused by antibiotic resistant pathogens (eg:oxacillin resistant *Staphylococcus aureus*, *Pseudomonas aeruginosa*, and *enterobacter* species).(*Chaster J et al; 2007*).

Incidence:

Ventilator-associated pneumonia affects 8 to 20% of patients. Several risk factors have been reported to be associated with VAP, including the duration of ventilation, sepsis, acute respiratory distress syndrome (ARDS),

chronic pulmonary disease, and neurological disease(*Alvaro Rea-Neto et al; 2008*).

Mortality:

The mortality rates in patients with VAP range from 20 to 50% and may reach more than 70% when the infection is caused by multi-resistant and invasive pathogens (*Alvaro Rea-Neto et al; 2008*)

The incidence of VAP-attributable mortality is difficult to quantify due to the possible confounding effect of associated conditions, but VAP is thought to increase the mortality of the underlying disease by about 30%. VAP is also associated with considerable morbidity, including prolonged ICU length of stay, prolonged mechanical ventilation, and increased costs of hospitalization. (*Heyland et al;1999*).

Etiology:

Etiologic agent of VAP may differ according to patients, units, hospitals or countries, nevertheless, comorbid conditions, length of hospital stay and exposition of antimicrobials are the most important factors determining the etiologic agent (*Torres et al; 2001*).